Therefore, EM900 could be a better drug to prevent COPD exacerbation compared to erythromycin, although EM900 had smaller potent inhibitory effects on the expression of ICAM-1 than erythromycin. This evidence concerns the gene ICAM1 and chronic obstructive pulmonary disease.